vs
Side-by-side financial comparison of BILL Holdings, Inc. (BILL) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $414.7M, roughly 1.5× BILL Holdings, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.6%, a 35.1% gap on every dollar of revenue. On growth, BILL Holdings, Inc. posted the faster year-over-year revenue change (14.4% vs 4.8%). Over the past eight quarters, BILL Holdings, Inc.'s revenue compounded faster (13.3% CAGR vs 4.6%).
BILL Holdings, Inc. is an American company based in San Jose, California, that provides automated, cloud-based software for financial operations for small businesses in the United States. A white-labeled, end-to-end payments automation platform, Bill.com Connect is offered to financial institutions as part of their single sign-on online business banking ecosystem.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BILL vs RPRX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $414.7M | $622.0M |
| Net Profit | $-2.6M | $214.2M |
| Gross Margin | 79.8% | — |
| Operating Margin | -4.4% | 62.4% |
| Net Margin | -0.6% | 34.4% |
| Revenue YoY | 14.4% | 4.8% |
| Net Profit YoY | -107.7% | 2.9% |
| EPS (diluted) | $-0.03 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $414.7M | $622.0M | ||
| Q3 25 | $395.7M | $609.3M | ||
| Q2 25 | $383.3M | $578.7M | ||
| Q1 25 | $358.2M | $568.2M | ||
| Q4 24 | $362.6M | $593.6M | ||
| Q3 24 | $358.4M | $564.7M | ||
| Q2 24 | $343.7M | $537.3M | ||
| Q1 24 | $323.0M | $568.0M |
| Q4 25 | $-2.6M | $214.2M | ||
| Q3 25 | $-3.0M | $288.2M | ||
| Q2 25 | $-7.1M | $30.2M | ||
| Q1 25 | $-11.6M | $238.3M | ||
| Q4 24 | $33.5M | $208.2M | ||
| Q3 24 | $8.9M | $544.0M | ||
| Q2 24 | $7.6M | $102.0M | ||
| Q1 24 | $31.8M | $4.8M |
| Q4 25 | 79.8% | — | ||
| Q3 25 | 80.5% | — | ||
| Q2 25 | 80.8% | — | ||
| Q1 25 | 81.2% | — | ||
| Q4 24 | 81.6% | — | ||
| Q3 24 | 82.0% | — | ||
| Q2 24 | 81.0% | — | ||
| Q1 24 | 83.0% | — |
| Q4 25 | -4.4% | 62.4% | ||
| Q3 25 | -5.2% | 70.1% | ||
| Q2 25 | -5.8% | 36.3% | ||
| Q1 25 | -8.1% | 94.0% | ||
| Q4 24 | -6.0% | 60.9% | ||
| Q3 24 | -2.1% | — | ||
| Q2 24 | -6.5% | 50.2% | ||
| Q1 24 | -8.6% | -13.0% |
| Q4 25 | -0.6% | 34.4% | ||
| Q3 25 | -0.7% | 47.3% | ||
| Q2 25 | -1.8% | 5.2% | ||
| Q1 25 | -3.2% | 41.9% | ||
| Q4 24 | 9.3% | 35.1% | ||
| Q3 24 | 2.5% | 96.3% | ||
| Q2 24 | 2.2% | 19.0% | ||
| Q1 24 | 9.8% | 0.8% |
| Q4 25 | $-0.03 | $0.49 | ||
| Q3 25 | $-0.03 | $0.67 | ||
| Q2 25 | $0.02 | $0.07 | ||
| Q1 25 | $-0.11 | $0.55 | ||
| Q4 24 | $-0.06 | $0.46 | ||
| Q3 24 | $0.08 | $1.21 | ||
| Q2 24 | $0.37 | $0.23 | ||
| Q1 24 | $0.00 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $618.7M |
| Total DebtLower is stronger | $1.8B | $9.0B |
| Stockholders' EquityBook value | $3.8B | $9.7B |
| Total Assets | $10.1B | $19.6B |
| Debt / EquityLower = less leverage | 0.48× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $618.7M | ||
| Q3 25 | $1.1B | $938.9M | ||
| Q2 25 | $1.0B | $631.9M | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.6B | $929.0M | ||
| Q3 24 | $853.5M | $950.1M | ||
| Q2 24 | $985.9M | $1.8B | ||
| Q1 24 | $952.5M | $843.0M |
| Q4 25 | $1.8B | $9.0B | ||
| Q3 25 | $1.9B | $8.9B | ||
| Q2 25 | $1.7B | $8.0B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.7B | $7.6B | ||
| Q3 24 | $914.8M | $7.6B | ||
| Q2 24 | $914.0M | $7.6B | ||
| Q1 24 | $1.1B | $6.1B |
| Q4 25 | $3.8B | $9.7B | ||
| Q3 25 | $3.9B | $9.6B | ||
| Q2 25 | $3.9B | $9.5B | ||
| Q1 25 | $3.9B | $9.8B | ||
| Q4 24 | $3.8B | $10.3B | ||
| Q3 24 | $4.0B | $10.3B | ||
| Q2 24 | $4.1B | $9.8B | ||
| Q1 24 | $4.1B | $9.9B |
| Q4 25 | $10.1B | $19.6B | ||
| Q3 25 | $10.2B | $19.3B | ||
| Q2 25 | $10.1B | $18.3B | ||
| Q1 25 | $9.6B | $17.6B | ||
| Q4 24 | $9.7B | $18.2B | ||
| Q3 24 | $9.0B | $18.0B | ||
| Q2 24 | $9.2B | $17.7B | ||
| Q1 24 | $9.1B | $16.1B |
| Q4 25 | 0.48× | 0.92× | ||
| Q3 25 | 0.48× | 0.93× | ||
| Q2 25 | 0.44× | 0.84× | ||
| Q1 25 | 0.43× | 0.78× | ||
| Q4 24 | 0.44× | 0.74× | ||
| Q3 24 | 0.23× | 0.74× | ||
| Q2 24 | 0.22× | 0.78× | ||
| Q1 24 | 0.28× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $105.3M | $827.1M |
| Free Cash FlowOCF − Capex | $103.8M | — |
| FCF MarginFCF / Revenue | 25.0% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $378.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.3M | $827.1M | ||
| Q3 25 | $96.9M | $702.6M | ||
| Q2 25 | $83.8M | $364.0M | ||
| Q1 25 | $99.5M | $596.1M | ||
| Q4 24 | $78.7M | $742.5M | ||
| Q3 24 | $88.6M | $703.6M | ||
| Q2 24 | $78.6M | $658.2M | ||
| Q1 24 | $66.8M | $664.6M |
| Q4 25 | $103.8M | — | ||
| Q3 25 | $95.6M | — | ||
| Q2 25 | $81.0M | — | ||
| Q1 25 | $98.4M | — | ||
| Q4 24 | $78.3M | — | ||
| Q3 24 | $88.6M | — | ||
| Q2 24 | $78.4M | — | ||
| Q1 24 | $66.8M | — |
| Q4 25 | 25.0% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 21.1% | — | ||
| Q1 25 | 27.5% | — | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 22.8% | — | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.35× | 3.57× | ||
| Q3 24 | 9.94× | 1.29× | ||
| Q2 24 | 10.35× | 6.45× | ||
| Q1 24 | 2.10× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BILL
| Accounts Payable And Accounts Receivable Solutions | $185.9M | 45% |
| Spend And Expense Interchange Revenue | $166.5M | 40% |
| Interest On Funds Held For Customers | $39.5M | 10% |
| Embedded And Other Solutions | $22.8M | 5% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
